Serum estradiol levels associated with specific gene expression patterns in normal breast tissue and in breast carcinomas

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Haakensen, Vilde D ^a,b   Bjøro, Trine ^a,b   Lüders, Torben ^c   Riis, Margit ^c,d   Bukholm, Ida K ^b,d   Kristensen, Vessela N ^a,b,c   Troester, Melissa A ^e   Homen, Marit M ^f   Ursin, Giske ^g,h,i   Børresen Dale, Anne Lise ^a,b   Helland, Åslaug ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^d Akerhus University Hospital   (Norway)

^e University of North Carolina at Chapel Hill   (United States)

^f UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^g UNIVERSITY OF OSLO   (Norway)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ CANCER REGISTRY OF NORWAY   (Norway)

Author keywords

AREG; COX1; Gene expression; GREB1TFF; HIN1; Normal breast tissue; PTGS1; SCGB3A1; Serum estradiol; TLN2

Indexed keywords

AROMATASE; CELL PROTEIN; ESTRADIOL; ESTROGEN RECEPTOR; FOLLITROPIN; LUTEINIZING HORMONE; PROGESTERONE; PROLACTIN; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE 1; PROTEIN AREG; PROTEIN GREB1; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; UNCLASSIFIED DRUG; CYCLOOXYGENASE 1; CYTOKINE; DCLK1 PROTEIN, HUMAN; MEMBRANE PROTEIN; PROTEIN SERINE THREONINE KINASE; PTGS1 PROTEIN, HUMAN; RSPO1 PROTEIN, HUMAN; SCGB3A1 PROTEIN, HUMAN; SIGNAL PEPTIDE; SLITRK4 PROTEIN, HUMAN; TALIN; THROMBOSPONDIN; TLN2 PROTEIN, HUMAN; TRANSCRIPTOME; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST CELL; CANCER INHIBITION; CANCER INVASION; CANCER PATIENT; CANCER RISK; CELL SPECIFICITY; COHORT ANALYSIS; CONTROLLED STUDY; DCLK1 GENE; ESTRADIOL BLOOD LEVEL; ESTROGEN SYNTHESIS; FEMALE; GENE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE SILENCING; GENETIC ASSOCIATION; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; LUMINAL CELL; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MICROARRAY ANALYSIS; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; PROTEIN METHYLATION; PTGS1 GENE; RSPO1 GENE; SCGB3A1 GENE; SLITRK4 GENE; TLN2 GENE; TUMOR SUPPRESSOR GENE; ADULT; AGED; BLOOD; BREAST; BREAST TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETICS; INTRADUCTAL CARCINOMA; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PAGET NIPPLE DISEASE; STATISTICAL MODEL;

ADULT; AGED; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CYCLOOXYGENASE 1; CYTOKINES; ESTRADIOL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LINEAR MODELS; MEMBRANE PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN-SERINE-THREONINE KINASES; TALIN; THROMBOSPONDINS; TRANSCRIPTOME; TUMOR SUPPRESSOR PROTEINS;

EID: 79961005126     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-332     Document Type: Article

References (51)

1. Russo J, Russo IH. Development of the human breast. Maturitas 2004, 49:2-15. 10.1016/j.maturitas.2004.04.011, 15351091.
2. Burger H. The Menopausal Transition -- Endocrinology. Journal of Sexual Medicine 2008, 5:2266-2273.
3. Zhang HZ, Bennett JM, Smith KT, Sunil N, Haslam SZ. Estrogen mediates mammary epithelial cell proliferation in serum-free culture indirectly via mammary stroma-derived hepatocyte growth factor. Endocrinology 2002, 143:3427-3434. 10.1210/en.2002-220007, 12193555.
4. Key TJ. Serum oestradiol and breast cancer risk. Endocr Relat Cancer 1999, 6:175-180. 10.1677/erc.0.0060175, 10731106.
5. Cavalieri EL, Stack DE, Devanesan PD, Todorovic R, Dwivedy I, Higginbotham S, Johansson SL, Patil KD, Gross ML, Gooden JK, et al. Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc Natl Acad Sci USA 1997, 94:10937-10942. 10.1073/pnas.94.20.10937, 23537, 9380738.
6. Hankinson SE. Endogenous hormones and risk of breast cancer in postmenopausal women. Breast Dis 2005, 24:3-15.
7. Tuma R. Mimicking pregnancy to reduce breast cancer risk. J Natl Cancer Inst 2010, 102:517-518. 10.1093/jnci/djq146, 20388876.
8. Clarke RB, Howell A, Potten CS, Anderson E. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 1997, 57:4987-4991.
9. Saji S, Sakaguchi H, Andersson S, Warner M, Gustafsson J. Quantitative analysis of estrogen receptor proteins in rat mammary gland. Endocrinology 2001, 142:3177-3186. 10.1210/en.142.7.3177, 11416040.
10. Dunbier AK, Anderson H, Ghazoui Z, Folkerd EJ, A'hern R, Crowder RJ, Hoog J, Smith IE, Osin P, Nerurkar A, et al. Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women. J Clin Oncol 2010, 28:1161-1167. 10.1200/JCO.2009.23.9616, 2834467, 20124184.
11. Duan R, Xie W, Li X, McDougal A, Safe S. Estrogen regulation of c-fos gene expression through phosphatidylinositol-3-kinase-dependent activation of serum response factor in MCF-7 breast cancer cells. Biochem Biophys Res Commun 2002, 294:384-394. 10.1016/S0006-291X(02)00499-0, 12051724.
12. Yusuf R, Frenkel K. Morphologic transformation of human breast epithelial cells MCF-10A: dependence on an oxidative microenvironment and estrogen/epidermal growth factor receptors. Cancer Cell Int 2010, 10:30. 10.1186/1475-2867-10-30, 2944135, 20809984.
13. Kristensen VN, Sorlie T, Geisler J, Yoshimura N, Linegjaerde OC, Glad I, Frigessi A, Harada N, Lonning PE, Borresen-Dale AL. Effects of anastrozole on the intratumoral gene expression in locally advanced breast cancer. J Steroid Biochem Mol Biol 2005, 95:105-111. 10.1016/j.jsbmb.2005.04.028, 16023338.
14. Geisler J, Detre S, Berntsen H, Ottestad L, Lindtjorn B, Dowsett M, Einstein LP. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res 2001, 7:1230-1236.
15. Haynes BP, Straume AH, Geisler J, A'hern R, Helle H, Smith IE, Lonning PE, Dowsett M. Intratumoral estrogen disposition in breast cancer. Clin Cancer Res 2010, 16:1790-1801. 10.1158/1078-0432.CCR-09-2481, 20215536.
16. Lonning PE, Helle H, Duong NK, Ekse D, Aas T, Geisler J. Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. J Steroid Biochem Mol Biol 2009, 117:31-41. 10.1016/j.jsbmb.2009.06.005, 19591931.
17. Wilson CL, Sims AH, Howell A, Miller CJ, Clarke RB. Effects of oestrogen on gene expression in epithelium and stroma of normal human breast tissue. Endocr Relat Cancer 2006, 13:617-628. 10.1677/erc.1.01165, 16728587.
18. Haakensen VD, Biong M, Lingjaerde OC, Holmen MM, Frantzen JO, Chen Y, Navjord D, Romundstad L, Luders T, Bukholm IK, et al. Expression levels of uridine 5'-diphospho-glucuronosyltransferase genes in breast tissue from healthy women are associated with mammographic density. Breast Cancer Res 2010, 12:R65. 10.1186/bcr2632, 2949660, 20799965.
19. Muggerud AA, Hallett M, Johnsen H, Kleivi K, Zhou W, Tahmasebpoor S, Amini RM, Botling J, Borresen-Dale AL, Sorlie T, et al. Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer. Mol Oncol 2010, 4:357-368. 10.1016/j.molonc.2010.06.007, 20663721.
20. Stanford Microarray Database. , http://genome-www5.stanford.edu/
21. R library impute.knn. , http://rss.acs.unt.edu/Rdoc/library/impute/html/impute.knn.html
22. Ursin G, Astrahan MA, Salane M, Parisky YR, Pearce JG, Daniels JR, Pike MC, Spicer DV. The detection of changes in mammographic densities. Cancer Epidemiol Biomarkers Prev 1998, 7:43-47.
23. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001, 98:5116-5121. 10.1073/pnas.091062498, 33173, 11309499.
24. Significance Analysis of Microarrays. , http://www-stat.stanford.edu/~tibs/SAM/
25. DAVID Bioinformatics Resources 6.7. , http://david.abcc.ncifcrf.gov/
26. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de RM, Jeffrey SS, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
27. Cheng G, Li Y, Omoto Y, Wang Y, Berg T, Nord M, Vihko P, Warner M, Piao YS, Gustafsson JA. Differential regulation of estrogen receptor (ER)alpha and ERbeta in primate mammary gland. J Clin Endocrinol Metab 2005, 90:435-444.
28. Krop IE, Sgroi D, Porter DA, Lunetta KL, LeVangie R, Seth P, Kaelin CM, Rhei E, Bosenberg M, Schnitt S, et al. HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells. Proc Natl Acad Sci USA 2001, 98:9796-9801. 10.1073/pnas.171138398, 55532, 11481438.
29. Krop I, Parker MT, Bloushtain-Qimron N, Porter D, Gelman R, Sasaki H, Maurer M, Terry MB, Parsons R, Polyak K. HIN-1, an inhibitor of cell growth, invasion, and AKT activation. Cancer Res 2005, 65:9659-9669. 10.1158/0008-5472.CAN-05-1663, 16266985.
30. Park SY, Kwon HJ, Lee HE, Ryu HS, Kim SW, Kim JH, Kim IA, Jung N, Cho NY, Kang GH. Promoter CpG island hypermethylation during breast cancer progression. Virchows Arch 2010,
31. Krop I, Player A, Tablante A, Taylor-Parker M, Lahti-Domenici J, Fukuoka J, Batra SK, Papadopoulos N, Richards WG, Sugarbaker DJ, et al. Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types. Mol Cancer Res 2004, 2:489-494.
32. Krop I, Maguire P, Lahti-Domenici J, Lodeiro G, Richardson A, Johannsdottir HK, Nevanlinna H, Borg A, Gelman R, Barkardottir RB, et al. Lack of HIN-1 methylation in BRCA1-linked and "BRCA1-like" breast tumors. Cancer Res 2003, 63:2024-2027.
33. Vasilatos SN, Broadwater G, Barry WT, Baker JC, Lem S, Dietze EC, Bean GR, Bryson AD, Pilie PG, Goldenberg V, et al. CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis. Cancer Epidemiol Biomarkers Prev 2009, 18:901-914. 10.1158/1055-9965.EPI-08-0875, 2667866, 19258476.
34. Moulder SL. Does the PI3K Pathway Play a Role in Basal Breast Cancer?. Clin Breast Cancer 2010, 10:S66-S71. 10.3816/CBC.2010.s.014, 21115424.
35. Rosenberg LU, Magnusson C, Lindstrom E, Wedren S, Hall P, Dickman PW. Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study. Breast Cancer Res 2006, 8:R11. 10.1186/bcr1378, 1413980, 16507159.
36. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 1996, 137:5739-5742. 10.1210/en.137.12.5739, 8940410.
37. Kino Y, Kojima F, Kiguchi K, Igarashi R, Ishizuka B, Kawai S. Prostaglandin E2 production in ovarian cancer cell lines is regulated by cyclooxygenase-1, not cyclooxygenase-2. Prostaglandins Leukot Essent Fatty Acids 2005, 73:103-111. 10.1016/j.plefa.2005.04.014, 15963707.
38. Daikoku T, Wang D, Tranguch S, Morrow JD, Orsulic S, DuBois RN, Dey SK. Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Res 2005, 65:3735-3744. 10.1158/0008-5472.CAN-04-3814, 2584020, 15867369.
39. Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, Tiano HF, Morham SG, Smithies O, Langenbach R. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000, 60:4705-4708.
40. Frank B, Hoffmeister M, Klopp N, Llig T, Chang-Claude J, Brenner H. Polymorphisms in inflammatory pathway genes and their association with colorectal cancer risk. Int J Cancer 2010,
41. Androulidaki A, Dermitzaki E, Venihaki M, Karagianni E, Rassouli O, Andreakou E, Stournaras C, Margioris AN, Tsatsanis C. Corticotropin Releasing Factor promotes breast cancer cell motility and invasiveness. Mol Cancer 2009, 8:30. 10.1186/1476-4598-8-30, 2697132, 19490624.
42. Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998, 90:455-460. 10.1093/jnci/90.6.455, 9521170.
43. Debrand E, El JY, Spence L, Bate N, Praekelt U, Pritchard CA, Monkley SJ, Critchley DR. Talin 2 is a large and complex gene encoding multiple transcripts and protein isoforms. FEBS J 2009, 276:1610-1628. 10.1111/j.1742-4658.2009.06893.x, 2702505, 19220457.
44. Conti FJ, Monkley SJ, Wood MR, Critchley DR, Muller U. Talin 1 and 2 are required for myoblast fusion, sarcomere assembly and the maintenance of myotendinous junctions. Development 2009, 136:3597-3606. 10.1242/dev.035857, 2761109, 19793892.
45. Demura M, Martin RM, Shozu M, Sebastian S, Takayama K, Hsu WT, Schultz RA, Neely K, Bryant M, Mendonca BB, et al. Regional rearrangements in chromosome 15q21 cause formation of cryptic promoters for the CYP19 (aromatase) gene. Hum Mol Genet 2007, 16:2529-2541. 10.1093/hmg/ddm145, 17584767.
46. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 2003, 144:4562-4574. 10.1210/en.2003-0567, 12959972.
47. Yau C, Fedele V, Roydasgupta R, Fridlyand J, Hubbard A, Gray JW, Chew K, Dairkee SH, Moore DH, Schittulli F, et al. Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers. Breast Cancer Res 2007, 9:R59. 10.1186/bcr1765, 2216076, 17850661.
48. Rae JM, Johnson MD, Scheys JO, Cordero KE, Larios JM, Lippman ME. GREB 1 is a critical regulator of hormone dependent breast cancer growth. Breast Cancer Res Treat 2005, 92:141-149. 10.1007/s10549-005-1483-4, 15986123.
49. Heaphy C, Griffith J, Bisoffi M. Mammary field cancerization: molecular evidence and clinical importance. Breast Cancer Research and Treatment 2009, 118:229-239. 10.1007/s10549-009-0504-0, 19685287.
50. Graham K, de las MA, Tripathi A, King C, Kavanah M, Mendez J, Stone M, Slama J, Miller M, Antoine G, et al. Gene expression in histologically normal epithelium from breast cancer patients and from cancer-free prophylactic mastectomy patients shares a similar profile. Br J Cancer 2010, 102:1284-1293. 10.1038/sj.bjc.6605576, 2855998, 20197764.
51. Troester MA, Lee MH, Carter M, Fan C, Cowan DW, Perez ER, Pirone JR, Perou CM, Jerry DJ, Schneider SS. Activation of host wound responses in breast cancer microenvironment. Clin Cancer Res 2009, 15:7020-7028. 10.1158/1078-0432.CCR-09-1126, 2783932, 19887484.